InterContinental Hotels Group PLC (the “Company”)
Purchase of own shares
LONDON, UK / ACCESS Newswire / March 27, 2026 / The Company announces that on 26 March 2026 it purchased the following number of its ordinary shares of 20340/399 pence each through Goldman Sachs International (“GSI“) on the London Stock Exchange in accordance with the authority granted by shareholders at the Company’s Annual General Meeting on 8 May 2025 (the “Purchase“). The Purchase was effected pursuant to instructions issued by the Company on 17 February 2026, as announced on 17 February 2026.
|
Date of purchase: |
26 March 2026 |
|
|
Aggregate number of ordinary shares purchased: |
26,132 |
|
|
Lowest price paid per share: |
$ 131.9000 |
|
|
Highest price paid per share: |
$ 133.6000 |
|
|
Average price paid per share: |
$ 132.7615 |
The Company intends to cancel the purchased shares.
Following the above transaction, the Company has 150,391,674 ordinary shares in issue (excluding 5,431,782 held in treasury).
A full breakdown of the individual purchases by GSI is included below.
http://www.rns-pdf.londonstockexchange.com/rns/3486Y_1-2026-3-26.pdf
Enquiries to:
InterContinental Hotels Group PLC:
Investor Relations: Stuart Ford (+44 (0)7823 828 739); Kate Carpenter (+44 (0) 7825 655 702);
Joe Simpson (+44 (0)7976 862 072)
Media Relations: Neil Maidment (+44 (0)7970 668 250); Mike Ward (+44 (0)7795 257 407)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: InterContinental Hotels Group PLC
View the original press release on ACCESS Newswire
IIG's constructed, owned-and-operated northern corridor is attracting strong customer demand, with further expansion already under…
As of the 2025 filing season, the IRS is applying First-Time Abatement automatically - without…
WASHINGTON, DC / ACCESS Newswire / June 8, 2026 / AGS Health®, a leading provider…
Proof-of-concept SHEPHERD study will assess SUL-238's effects on mitochondrial function in patients with Parkinson's disease.…
FAIRFIELD, NJ / ACCESS Newswire / June 8, 2026 / Jerash Holdings (US), Inc. (Nasdaq:JRSH),…
Building the Olfactory Layer of Physical AIHighlighting Progress Across Semiconductor Manufacturing, Healthcare Infrastructure and Physical…